Acorda Therapeutics Inc. (ACOR)

7.28
0.26 3.45
NASDAQ : Health Technology
Prev Close 7.54
Open 7.58
Day Low/High 7.26 / 7.86
52 Wk Low/High 6.96 / 31.10
Volume 683.50K
Avg Volume 829.30K
Exchange NASDAQ
Shares Outstanding 48.13M
Market Cap 368.68M
EPS 0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Acorda Announces Patent Trials And Appeal Board (PTAB) Institutes IPRs Of AMPYRA Patents

Acorda Announces Patent Trials And Appeal Board (PTAB) Institutes IPRs Of AMPYRA Patents

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) has instituted the inter partes review (IPR) of U.

Acorda Therapeutics, Inc. Will Commence The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 11 March 2016

Acorda Therapeutics, Inc. Will Commence The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 11 March 2016

As announced on 19 January 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") and Biotie Therapies Corp.

Acorda Has Filed Tender Offer Document Relating To Public Tender Offer For Biotie Therapies With Finnish Financial Supervisory Authority

Acorda Has Filed Tender Offer Document Relating To Public Tender Offer For Biotie Therapies With Finnish Financial Supervisory Authority

As announced on January 19, 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) ("Acorda") and Biotie Therapies Corp.

Acorda Therapeutics To Present At Two Investor Conferences In March

Acorda Therapeutics To Present At Two Investor Conferences In March

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during March.

Acorda Announces Expiration Of The Hart-Scott-Rodino Waiting Period For Its Tender Offer For Biotie Therapies

Acorda Announces Expiration Of The Hart-Scott-Rodino Waiting Period For Its Tender Offer For Biotie Therapies

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), for its tender offer for Biotie Therapies Corp.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BRKR, GCO, MOS, TOWR Downgrades: ACOR, AF, CFG, CHGG, DISH, DLHC, DVA, ECOL, ETFC, GTIM, HPT, K, NATL, NEWT, NR, OHI, OLP, PPC, RHT, SCSS, SLF, TEO, TRI, TRIP, TRP, VEEV, VG, WWE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2015

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2015

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the fourth quarter and full year ended December 31, 2015.

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during February.

Acorda To Host Conference Call To Discuss Fourth Quarter And Year End 2015 Results On February 11, 2016

Acorda To Host Conference Call To Discuss Fourth Quarter And Year End 2015 Results On February 11, 2016

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter and year end 2015 financial results and pipeline updates on Thursday, February 11 at 8:30 a.

Acorda Therapeutics (ACOR) Stock: Weak On High Volume Today

Acorda Therapeutics (ACOR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a weak on high relative volume candidate

7 Stocks to Trade for Breakouts on Big Volume

7 Stocks to Trade for Breakouts on Big Volume

These stocks trading on unusual volume are within range of triggering breakout trades.

Acorda Acquires Parkinson's Drug Through Biotie Buyout

Acorda Acquires Parkinson's Drug Through Biotie Buyout

Acorda's all-cash tender offer values Biotie at $363 million, or $25.60 per ADS, representing a 96% premium over the stock's closing price on Friday.

European Stocks Follow Asia Higher as China GDP Revives Hopes for Stimulus

European Stocks Follow Asia Higher as China GDP Revives Hopes for Stimulus

European stocks rise on Tuesday, following gains across Asia, as Chinese GDP figures are no worse than expected yet weak enough to revive hopes of government stimulus.

Acorda To Acquire Biotie Therapies

Acorda To Acquire Biotie Therapies

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered into an agreement to acquire Biotie Therapies Corp.

Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance And 2016/2017 Clinical Milestones At J.P. Morgan Healthcare Conference

Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance And 2016/2017 Clinical Milestones At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2015 of $121 million.

Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference

Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that it will present at the 34 th Annual J.

Acorda Announces Departure Of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. As Interim CMO

Acorda Announces Departure Of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. As Interim CMO

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Chief Medical Officer (CMO) Enrique Carrazana, M.

Acorda Presents Analyses On Use Of Healthcare Services For Seizure Clusters At American Epilepsy Society Annual Meeting

Acorda Presents Analyses On Use Of Healthcare Services For Seizure Clusters At American Epilepsy Society Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced analyses from a study showing the effect of rescue medication for seizure clusters on both clinical outcomes and healthcare resource utilization.

Acorda Initiates Phase 1 Clinical Trial Of CVT-427, Inhaled Therapy For Acute Treatment Of Migraines

Acorda Initiates Phase 1 Clinical Trial Of CVT-427, Inhaled Therapy For Acute Treatment Of Migraines

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced initiation of enrollment in the first clinical study of CVT-427, an investigational agent under development for the acute treatment of migraines.

Acorda Therapeutics To Present At The Oppenheimer Annual Healthcare Conference

Acorda Therapeutics To Present At The Oppenheimer Annual Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Oppenheimer Healthcare Conference in New York on Tuesday, December 8 at 11:30 am.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: A, ACLS, ACOR, CMCT, COHR, CTRP, GTN, GTN.A, HMHC, IESC, JCTCF, MCBC, NTAP, OKSB, QLGC, RBCAA, SCAI, SPLS, STAY, STS, SVT, TIK, WCIC, WSCI Downgrades: AAN, AKO.A, AREX, CIX, CRM, ESRT, FSBK, FTD, GPRE, JACK Initiations: PINC, VSLR, YUMA Read on to get TheStreet Quant Ratings' detailed report:

Acorda Therapeutics To Present At Two Investor Conferences In November

Acorda Therapeutics To Present At Two Investor Conferences In November

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during November.

Acorda Therapeutics (ACOR) Strong On High Relative Volume Today

Acorda Therapeutics (ACOR) Strong On High Relative Volume Today

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a strong on high relative volume candidate

Acorda Provides Financial And Pipeline Update For 2015 Third Quarter

Acorda Provides Financial And Pipeline Update For 2015 Third Quarter

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the third quarter ended September 30, 2015.

Insider Trading Alert - ACOR, CMCT And NUAN Traded By Insiders

Insider Trading Alert - ACOR, CMCT And NUAN Traded By Insiders

Stocks with insider trader activity include ACOR, CMCT and NUAN

Acorda Therapeutics To Host Conference Call To Discuss Third Quarter Results On October 22, 2015

Acorda Therapeutics To Host Conference Call To Discuss Third Quarter Results On October 22, 2015

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will host a conference call and webcast to report its third quarter 2015 financial results and pipeline updates on Thursday, October 22 at 8:30 a.

Insider Trading Alert - ACOR, TIPT And NUAN Traded By Insiders

Insider Trading Alert - ACOR, TIPT And NUAN Traded By Insiders

Stocks with insider trader activity include ACOR, TIPT and NUAN

Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new analyses of pharmacokinetic data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS), and...

Acorda Therapeutics (ACOR) Is Today's Perilous Reversal Stock

Acorda Therapeutics (ACOR) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate

Acorda Recognized With Legal Media Group 2015 Life Sciences Award

Acorda Recognized With Legal Media Group 2015 Life Sciences Award

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that its legal team has been recognized with a Legal Media Group 2015 Life Sciences Award as a "Hatch-Waxman Impact Case of the Year.

TheStreet Quant Rating: D (Sell)